WILMINGTON, Mass., June 4, 2015 /PRNewswire/ -- Implant
Sciences Corporation (OTCQB: IMSC), a leading manufacturer of
explosives trace detection (ETD) and drugs trace detection
solutions for homeland security applications, today announced that
it has sold 16 of its QS-B220 desktop explosives trace detectors to
four major international airports in Poland.
Over the last seven weeks, Implant Sciences has announced the
sale of over 200 QS-B220 systems to major international airports
across five EU countries.
"The selection of Implant Sciences' QS-B220 by these Polish
airports once again underscores the value and capabilities of our
technology. As air transport continues to grow in
Poland and is a key driver of the
Polish economy, we are pleased to be part of the aviation security
infrastructure of the country," stated Richard Nelson, Implant Sciences' General
Manager of EMEA.
"Our experience shows that one country often looks to another in
purchasing decisions, and we believe that our system is being
recognized as the top performer in the industry, which is leading
to incredible momentum for our QS-B220 throughout
Europe," added Dr. Darryl Jones, Implant Sciences' Vice President
of Global Sales and Marketing. "But most importantly, these
airports recognize the QS-B220's strong value proposition, which
boasts a low cost of operation, the lowest false alarm rate, and
ease of use for operators."
"Our ability to deliver our products to customers, when they
want them, has also spurred our momentum in Europe," continued Dr. Jones. "When an airport
wants to add to their aviation security capabilities, they don't
usually want new systems in the distant future, they want them now.
We are pleased to be able to put our system in the hands of Polish
aviation security professionals."
About the QS-B220 Desktop Explosives Trace Detector
The QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly
detect and identify trace amounts of a wide variety of military,
commercial, and homemade explosives. With significantly lower
maintenance requirements than competing systems, the QS-B220 can be
deployed for a much lower total cost of ownership than other
approved products. Featuring a radioactive material-free design,
push-button maintenance and diagnostics, and a patented inCalâ„¢
internal automatic calibration system, the QS-B220 brings new
levels of performance and convenience to desktop trace detection
users with unsurpassed ease of use.
About Implant Sciences
Implant Sciences is a leader in developing and manufacturing
advanced detection capabilities to counter and eliminate the
ever-evolving threats from explosives and drugs. The Company's team
of dedicated trace detection experts has developed proprietary
technologies used in its commercial products, thousands of which
have been sold across more than 60 countries worldwide. The
Company's ETDs have received approvals and certifications from
several international regulatory agencies including the TSA in the
U.S., ECAC in Europe, CAAC and the
Ministry of Public Safety in China, Russia FSB, STAC in France, and the German Ministry of the
Interior. It has also received the GSN Homeland Security Award for
"Best Explosives Detection Solution" two years in a row (2013 and
2014). All Implant Sciences products are recognized as
Qualified Anti-Terrorism Technologies by the Department of Homeland
Security. For further details on the Company and its products,
please visit the Company's website at www.implantsciences.com.
Cautionary Note Regarding Forward-Looking Statements
This press release and any statements of employees,
representatives and partners of Implant Sciences Corporation (the
"Company") related thereto contain or may contain certain
"forward-looking statements," as that term is defined in the
Private Securities Litigation Reform Act of 1995. Such
statements may include, without limitation, statements with respect
to the Company's plans, objectives, projections, expectations and
intentions and other statements identified by words such as
"projects," "may," "will," "could," "would," "should," "believes,"
"expects," "anticipates," "estimates," "intends," "plans,"
"potential" or similar expressions. Such statements are based
on management's current expectations and are subject to significant
risks and uncertainties (many of which are beyond the Company's
control) that could cause the Company's actual results to differ
materially from the forward-looking statements. Such risks
and uncertainties include, but are not limited to, the risks that
there is no guaranty that the Transportation Security
Administration (TSA) or any other U.S. or foreign government and
law enforcement agencies or commercial consumers will purchase any
of our explosives detection products or that any new products we
may develop will be accepted by the TSA or by such other
governments, agencies or consumers; economic, political and other
risks associated with international sales and operations could
adversely affect our sales; our business is subject to intense
competition and rapid technological change, and our ability to
generate revenue and profit will depend on our ability to develop
and introduce new products; and other risks and uncertainties
described in our filings with the Securities and Exchange
Commission, including our most recent Forms 10-K, 10-Q and
8-K. In light of these risks and uncertainties, readers are
cautioned that actual results may differ significantly from those
described or anticipated in the forward-looking statements.
The Company undertakes no obligation to publicly update any
forward-looking statements, whether as a result of new information,
future presentations or otherwise, except as required by applicable
law.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/four-major-airports-in-poland-join-other-european-airports-in-selecting-implant-sciences-qs-b220-trace-detectors-to-meet-european-security-regulations-300094058.html
SOURCE Implant Sciences Corporation